These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24947099)

  • 1. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
    Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
    Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
    Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
    Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
    J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
    Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
    Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of BRAF V600E mutation in the differential diagnosis of follicular and papillary tumors of the thyroid and for the optimization of thearpy].
    Semënov DIu; Boriskova ME; Zaraĭskiĭ MI; Saburova IIu; Pankova PA; Farafonova UV; Bykov MA
    Vopr Onkol; 2012; 58(5):649-52. PubMed ID: 23600282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
    Sahoo S; Hoda SA; Rosai J; DeLellis RA
    Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.
    Handkiewicz-Junak D; Czarniecka A; Jarzab B
    Mol Cell Endocrinol; 2010 Jun; 322(1-2):8-28. PubMed ID: 20138116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
    Raphael SJ; McKeown-Eyssen G; Asa SL
    Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
    Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
    Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
    Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
    Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.